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Inhibition of experimental neointimal hyperplasia
and neoatherosclerosis by local, stent-mediated
delivery of everolimus
Hugh Q. Zhao, PhD,a Alexander Nikanorov, MD, PhD,a Renu Virmani, MD,b and
Lewis B. Schwartz, MD,a Abbott Park, Ill; and Gaithersburg, Md
Introduction: A novel self-expanding, drug-eluting stent (DES) was designed to slowly release everolimus in order to
prevent restenosis after percutaneous peripheral intervention. The purpose of this experimental animal study was to test
the hypothesis that long-term local, stent-mediated delivery of everolimus would reduce neointimal hyperplasia in
porcine iliac arteries.
Methods: The iliac arteries of 24 Yucatan mini-swine were percutaneously treated with overlapping 8-  28-mm
self-expanding nitinol stents loaded with everolimus (225 g/cm2 stent surface area) formulated in a poly(ethylene-co-
vinyl alcohol) copolymer intended to deliver the drug in a sustained fashion over about 6 months (DES). Bare nitinol
self-expanding stents (bare metal stent [BMS]) were implanted in an identical fashion on the contralateral side to serve
as controls. After 3, 6, or 12 months, the animals were sacrificed and the stented arteries perfusion-fixed for
histomorphometric analysis.
Results: The chronic presence of everolimus in arterial tissue reduced stent-induced inflammation after 3 months
(inflammation score: BMS 2.29  0.44 vs DES 0.17  0.17; P  .001) and 6 months (BMS 2.06  0.43 vs DES 0.50
 0.5; P  .007), although some late inflammation was observed after drug exhaustion (BMS 1.00  0.25 vs DES 2.56
 0.62 after 12 months; P  not significant [NS]). Treatment with locally delivered everolimus significantly reduced
neointimal hyperplasia after 3 months (neointimal thickness: BMS 0.79  0.20 vs DES 0.37  0.04 mm; P  .03) and
6months (BMS 0.73 0.14 vs DES 0.41 0.08mm; P .05), although the effect had dissipated after 12months (BMS
0.68  0.11 vs DES 0.67  0.11 mm; P  NS). Remarkably, stent-induced neoatherosclerosis, characterized by the
histologic presence of foamy macrophages and cholesterol clefts, was significantly attenuated by treatment with
everolimus (atherogenic change scores at 3 months: BMS 0.56  0.15 vs DES 0.04  0.04; P  .003; 6 months: BMS
0.84  0.23 vs DES 0.00  0.00; P  .004; and 12 months: BMS 0.09  0.10 vs DES 0.19  0.19; P  NS).
Conclusions: In this experimental animal model, local arterial stent-mediated delivery of everolimus inhibited the
formation of neointimal hyperplasia and neoatherosclerosis during the first 6 months. The effect was transient, however,
as arterial morphology and histology appeared similar to control stented arteries after 12 months. (J Vasc Surg 2012;56:
1680-8.)
Clinical Relevance: Atherosclerotic vascular disease and its sequelae remain the single greatest killers in the world.
Significant advances have been made in the development of endovascular techniques for both coronary and peripheral
interventions. Although almost always successful technically, 30% to 50% of stent-based coronary and peripheral
interventions will fail during the first year. In the coronary arteries, this problem has largely been circumvented by the
development of drug-eluting stents. To date, however, drug-eluting stents have been found to be only marginally helpful
in the peripheral circulation. The purpose of this experimental animal study was to test the hypothesis that long-term
local, stent-mediated delivery of everolimus would reduce neointimal hyperplasia in porcine peripheral arteries.
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pAtherosclerosis remains the leading cause of death and
disability worldwide. The clinical events generated by ath-
erosclerotic plaques, including myocardial infarction,
stroke, renal failure, and amputation, are responsible for 17
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1680illion deaths per year.1 Given its prevalence and impact,
he prevention and treatment of atherosclerosis has been a
ajor focus of the medical community for decades. Proven
herapeutic strategies are comprised of three basic catego-
ies: lifestyle modification (control of body weight, habitual
hysical activity, and avoidance of tobacco products), sys-
emic drug therapy (antihypertension, lipid-lowering,
latelet inhibition, and/or plaque stabilization), and inva-
ive mechanical revascularization.
The invasive treatment of established atherosclerotic
esions comprises the single largest category of major oper-
tions in the world, including over 6 million surgical
nd/or interventional procedures performed annually.
pen surgical procedures designed to remove or exclude
laques have been performed since the 1950s and some
perations, such as coronary artery bypass grafting, periph-
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Volume 56, Number 6 Zhao et al 1681eral vascular bypass grafting, and carotid endarterectomy,
are ubiquitous. More recently, catheter-based therapies,
including percutaneous transluminal angioplasty and stent-
ing, have been developed. These minimally invasive tech-
niques can convert plaque-laden, occlusive coronary, pe-
ripheral and cerebrovascular segments to widely patent flow
channels without the need for open surgery. Although
almost always successful technically, 30% to 50% of stent-
based coronary and peripheral interventions will fail during
the first year due to the pathologic process of neointimal
hyperplasia and restenosis.2 In the coronary arteries, this
problem has largely been circumvented by the develop-
ment of drug-eluting stents (DESs), in which a relatively
low dose of antiproliferative drug is applied to an intravas-
cular stent for the purpose of inhibiting vascular smooth
muscle cell proliferation.3 DESs have also been found to be
useful in the tibial arteries as well, showing similar reduc-
tions in restenosis and reintervention.4,5 In the superficial
femoral artery (SFA), however, DESs have been largely
ineffectual, possibly due to (1) the larger plaque burden
and complexity of the SFA, (2) the continual and unpre-
dictable mechanical deformation of the SFA during sitting
and walking, and (3) the tendency of the peripheral arteries
toward profound neointimal hyperplasia in response to
intervention. The purpose of the experimental study de-
scribed herein was to test the hypothesis that a peripheral
DES with a relatively high drug dose and prolonged elution
profile would inhibit neointimal hyperplasia in a long-term
porcine model of percutaneous peripheral intervention
(PPI).
METHODS
Animal operations. Animal operations were con-
ducted at Synecor (Durham, NC), a test facility accredited
by the Association for the Assessment and Accreditation of
Laboratory Animal Care and registered with the United
States Department of Agriculture to conduct research on
laboratory animals. At least 1 day before the stent implant
procedure, 325 mg aspirin and 75 mg clopidogrel (Plavix,
Sanofi-Aventis, Bridgewater, NJ) were administered to
each animal per os as a daily single dose and continued until
study termination at the designated time points. After
induction of anesthesia, an incision was made in the neck to
expose the left carotid artery, an arterial sheath was intro-
Fig 1. The Dynalink-E everoduced and advanced into the vessel, and, under fluoros- iopy, a 0.035-inch guidewire was used to gain access to
arget arteries. Heparin (200 IU/kg) was administered
ntravenously to achieve an activated clotting time of250
econds. After baseline arterial dimensional measurements
ere obtained and recorded, DES and bare metal stent
BMS) self-expanding devices were deployed into opti-
ally sized regions of the left and right iliac arteries.
All conditions of testing conformed to the Animal
elfare Act (CFR 9) and its amendments. The protocol
as reviewed and approved by the Animal Care and Use
ommittee at the test facility for compliance with regula-
ions before study initiation.
Intravascular devices. The two test devices used in
his experiment were the Dynalink BMS (Abbott Labora-
ories, Abbott Park, Ill) and the Dynalink-E experimental
ES (Abbott). TheDynalink self-expanding stent (BMS) is
onstructed of nitinol, which is super-elastic at body tem-
erature. The 0.008-inch strut thickness design is based on
series of sinusoidal rings that are connected at six locations
round the circumference such that the connections are
ligned along the length of the stent and positioned 60°
rom each other.
The Dynalink-E experimental self-expanding DES (Fig
) is comprised of three components: (1) the Dynalink
itinol stent platform (described above), (2) a copolymer
oating matrix of poly(ethylene-co-vinyl alcohol; EVAL
mericas, Houston, Tex), and (3) the antiproliferative
rug everolimus (Certican, Zortress, and Afinitor; Novartis
harmaceuticals Corporation, Basel, Switzerland). EVAL is
semicrystalline polymer with a glass transition tempera-
ure of 55°C and melting point of 180°C. The chemical
ackbone is a C-C bond and the pendant group is -OH;
either contains hydrolytically or oxidatively labile chemi-
al bonds. The antiproliferative drug, everolimus, is a ther-
peutic agent originally developed for the prevention of
rgan transplant rejection, but it is also effective at inhibit-
ng the growth of certain solid tumors.6 It effectively inhib-
ts experimental vascular smooth muscle cell proliferation,
nhances vascular remodeling in animal models,7,8 and has
een shown to be safe and effective as the drug component
f coronary DES.9 The total drug load of Dynalink-E was
25 g/cm2 stent surface area; an 8-mm  28-mm device
ontained approximately 1 mg of everolimus.
Pharmacokinetic evaluation. Pharmacokinetic stud-
-eluting self-expanding stent.es were performed to assess everolimus distribution after a
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December 20121682 Zhao et altotal of 64Dynalink-E device implantations in 14 Yorkshire
Farm swine weighing 39 to 69 kg and 2 Yucatan Miniature
swine (180-day time point) weighing 31 to 33 kg. Four
devices were implanted in each animal, one each in the
bilateral iliac and deep femoral arteries. At each of the time
points (1, 3, 7, 14, 28, 56, 90, and 180 days, two animals
per time point), whole blood samples were collected (n 
2) and stented arteries were harvested and separated into
stent and tissue after death (n  8). Unstented artery
samples, approximately 5 mm in length, were harvested
from the distal edge of the device (n  8).
To assess arterial drug content long-term, 24 over-
lapped pairs of DESs were implanted into the iliac arteries
of 12 YucatanMiniature swine, 10 to 16months of age and
ranging in weight from 44 to 54 kg. Two overlapped DES
pairs were implanted in the bilateral iliac arteries of each
animal and harvested at 180, 270, and 360 days (n  8
stents in four animals per time point).
The drug remaining on the harvested stents was dis-
solved in 4 mL of N,N-dimethyl acetamide, extracted in
water-dimethyl acetamide (1:1) solution, and measured
using high-pressure liquid chromatography equipped with
a 3.0-  150-mm symmetry shield using a 5-m particle
size column maintained at 50°C with UV detection set at
277 nm. The isocratic mobile phase was composed of
50/50 (v/v) acetonitrile/water at 1.2 mL/minute.
Everolimus content in whole blood and arterial tissue ho-
mogenate was assayed by liquid chromatography equipped
with an SB-C18 (4.6- 12.5-mm, 5-m) cleanup column
(ambient, 5 mL/minute), an Inertsil ODS-3 (2.1-  50-
mm, 5-m; GL Sciences, Inc, Torrance, Calif) analytical
column (0.4 mL/minute) with mass spectroscopic detec-
tion. The lower limit of quantification of the blood and
arterial tissue assays was 0.0005 g/mL and 0.0005 g/g,
respectively.
Evaluation of long-term vascular response. To eval-
uate the long-term vascular response after BMS or DES
implantation, 24 overlapping pairs of 8-mm  28-mm
devices were implanted into the iliac arteries of 24 Yucatan
Miniature swine 11 to 18 months of age and weighing 35
to 56 kg. Each animal underwent a single interventional
procedure during which overlapped stent pairs of BMS or
DES were implanted in the bilateral iliac arteries. Each animal
received two overlapped BMSs in one iliac artery and two
overlapped DESs in the other. The target stent oversizing
ratio (nominal stent diameter-to-artery diameter ratio) was
1.1 to 1.4. Approximately one-third of each device was over-
lapped within the artery, and the right and left iliac arteries
were randomly assigned to receive BMS and DES pairs.
Animals were sacrificed and stented arteries explanted
at 3, 6, or 12 months after implantation (eight animals per
time point). Stented arteries were excised, dehydrated in a
graded series of ethanol, and embedded in methylmethac-
rylate resin. After polymerization, three 2- to 3-mm sec-
tions were sawed from each of the proximal, middle (over-
lapped), and distal arterial portions, ground to 40 to 50
m, polished, and stained with toluidine blue and basic
fuchsin. (Histologic assessment was performed using light mi-
roscopy by pathologists blinded to treatment assignment.
eri-strut inflammation was evaluated semiquantitatively
sing an ordinal scoring scale of 0 to 4 (0  none to
inimal, 1  mild, 2  moderate, 3  marked, and 4 
ranulomatous inflammation 25% of stent struts). Neo-
therosclerosis (newly formed atherosclerotic changes) was
lso scored using an ordinal scale of 0 to 4 (0  no
therogenic changes, 1  focal neointimal collections of
oam cells, 2  focal neointimal collections of foam cells
ith cholesterol deposition [necrotic core 5% of lesion
rea], 3 necrotic core with hemorrhage, and 4 rupture
f necrotic core).
Histomorphometric analysis was performed using dig-
tal morphometry to measure neointimal thickness, cross-
ectional areas, and area stenosis. Cross-sectional areas
easured included lumen, internal elastic lamina (IEL),
nd external elastic lamina. Histomorphometric percent
rea stenosis was calculated as 100 (IEL – lumen) IEL.
Statistical analysis. Histologic and morphometric
alues for the three sections in a given arterial segment were
veraged in order to report a single value. Data are pre-
ented as mean  SD unless otherwise noted. The paired
-test (continuous variables) or Wilcoxon/Kruskal-Wallis
ank-sum test were used to compare the treatment groups.
ests of significance were two-tailed and significance was
stablished by a value of P  .05.
ESULTS
Implantation and stent sizing. Devices were im-
lanted in all animals without complication, with oversized
atios of1.3 for all groups (3-month group: BMS 1.34
.05, DES 1.34  0.06; 6-month group: BMS 1.24 
.06, DES 1.26  0.09; and 12-month group: BMS 1.36
0.04, DES 1.35  0.04).
Pharmacokinetics. The release profile of everolimus
rom theDynalink-EDES is shown in Fig 2. Approximately
0% of the drug was eluted by 14 days then continued at a
lower rate over the next 3months. By the end of 6months,
he drug was almost completely exhausted from the stent
ig 2. In vivo profile of everolimus release from the drug-
olymer coating on the Dynalink-E nitinol self-expanding stent.96.9%  0.4%).
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Volume 56, Number 6 Zhao et al 1683Everolimus concentrations in whole blood, stented
arterial tissue, and adjacent unstented arterial segments are
shown in Fig 3. Whole blood concentrations of everolimus
were low and transient and, coupled with available human
pharmacokinetic data,10 suggest that the device can be
implanted without adverse systemic drug effects.11-13
Everolimus content in stented arteries was initially high
(10 g/g tissue after implantation) and, although it
could still be detected a full year after the procedure, this is
atypical of coronary DESs. Everolimus could also be de-
tected in unstented adjacent arterial segments, although
the amount of drug was one to two orders of magnitude
less than in the stented segment.
Long-term vascular responses after BMS and DES
implantation. All arteries and stents were patent at all
time points; there were no instances of arterial or stent
thrombosis in this study. Example histophotomicrographs
of overlapped stented arteries harvested at various time
points are shown in Fig 4.
Histologic and histomorphometric data are given in
the Table. There were no significant differences in stent
area between the groups; this was expected as the BMS and
DES stent platforms were mechanically identical. The
Dynalink-E DES significantly inhibited neointimal hyper-
plasia at both 3 and 6 months, as evidenced by the statisti-
cally significant attenuated neointimal thickness (P  .05).
The effect was transient, however, as there was no differ-
ence in neointimal thickness 1 year after treatment. The
decreased neointimal area in DES-treated arteries gener-
ated an increased lumen area as well as statistically signifi-
cant reductions in percent area stenosis. Again, the differ-
ences observed at 3 and 6 months were not reproduced
after 1 year.
The presence of everolimus attenuated the inflamma-
tory response to stenting at 3 and 6 months. Similar to the
morphometric observations, however, there were no statis-
Fig 3. In vivo everolimus concentrations in whole blood, stented
arteries, and unstented (adjacent) arterial tissues after implantation
of the Dynalink-E drug-eluting stent (DES). LLOQ, Lower limit
of quantitation.tically significant differences in inflammation score after 1 2ear; in fact, the DES score was nominally higher due to the
ccasional presence of granulomata, which were generally
ot observed after BMS implantation. Last, an unexpected
nding of the study was that everolimus inhibited the
ormation of neoatherosclerosis after stenting (Fig 5).
ompared to BMS, there were significant reductions in the
therogenic change scores for DES-treated arteries at both
months (BMS 0.56  0.15 vs DES 0.042  0.04; P 
003) and 6 months (BMS 0.84  0.23 vs DES 0.00 
.00; P  .004). Some late atherogenic changes were
bserved in DES-treated arteries after 12 months such that
he differences between BMSs and DESs were no longer
vident (BMS 0.094  0.10 vs DES 0.19  0.19; P 
927).
ISCUSSION
The impact of DES on the effectiveness of percutane-
us coronary intervention has been profound. In large-
cale clinical trials, coronary DESs that elute either siroli-
us, paclitaxel, or zotarolimus have been found to reduce
estenosis by 70% to 90% as compared to BMS.3 Second-
eneration devices that resist thrombosis as well as
estenosis quickly followed, and a recent meta-analysis en-
ompassing more than 17,000 patients suggests that second-
eneration everolimus-eluting coronary stents can be
mplanted with composite rates of myocardial infarction,
arget lesion revascularization, and stent thrombosis of only
.9%, 5.7%, and 0.7%, respectively.14 These newer-generation
ESs have been found to be efficacious in other vascular
eds as well. For instance, in patients with critical limb
schemia (CLI) from tibial artery occlusive disease, a recent
andomized trial comparing everolimus-eluting with bare
etal stents revealed that DESs significantly enhanced
-year primary patency (85% vs 54%; P  .0001) and
reedom from reintervention (95% vs 65%; P  .005).4
Unfortunately, DESs have met with considerably less
uccess in the larger and more complex SFA. For example,
he SIROCCO trial (SIROlimus Coated Cordis SMART
itinol Self-expandable Stent for the Treatment of Ob-
tructive Superficial Femoral Artery Disease), which com-
ared sirolimus-eluting vs bare metal nitinol self-
xpanding stents in SFA lesions of8 cm in length, showed
o significant differences in any morphologic or clinical
etric after 4 years.15 To date, the only successful trial of
ocal stent-based drug therapy in the SFA is the Zilver PTX
rial in which self-expanding nitinol Zilver stents (Cook
edical, Bloomington, Ind) were sprayed with paclitaxel
nd compared with nondrug stents in6 cm SFA lesions in
atients with peripheral arterial disease.16 The results
howed that the 61 patients who failed percutaneous
ransluminal angioplasty and were treated with “bailout”
ilver PTX stents enjoyed superior 1-year primary patency
o the 59 patients treated with “bailout” bare Zilver stents
90% vs 73%; P .009). However, the larger cohort of 246
atients with short-segment SFA lesions (mean, 5.43 cm)
xhibited a 1-year primary patency rate of only 83%, and
reliminary reports suggest that this rate may fall to 75% by
years.17 Thus, the antirestenotic effect of DES in the SFA
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percutaneous coronary intervention3 and represents only a
modest improvement over traditional bare metal stent-
ing.15,18-21 This is, perhaps, not surprising given that the
Zilver PTX device is not a DES per se. Because Zilver PTX
is created by direct application of paclitaxel without a
polymer, the 300-g/cm2 drug dose is immediately re-
leased upon deployment and not sustained over time.22
In contrast, the device examined in the present preclin-
ical study was designed as a “true” peripheral DES. The
Dynalink-E nitinol self-expanding DES is loaded with
225-g everolimus per cm2 stent area. The drug is applied
in conjunction with an EVAL polymer designed to slowly
release the drug in a diffusion-controlled manner over
several months.23 The experimental evidence suggests that
this design goal was met;50% of the drug is released by 2
weeks, 80% by 3 months, and 100% by 6 months. The
relatively high drug dose and long elution rate ensure that
the drug is durably delivered and sustained within the
arterial target tissue. Indeed, everolimus could still be de-
tected in experimental arterial tissue a full year after the
index implantation procedure.
Histologic examination of porcine arteries treated with
Dynalink-E in this experiment revealed that everolimus
exerted the anticipated antiproliferative effect. Arteries
treated with overlapped Dynalink-E stents exhibited statis-
tically significant decreased inflammation, neointimal
thickness, and percent area stenosis at both the 3- and
6-month time points. Historically, local antiproliferative
effects of DES of this magnitude and duration have been
notoriously difficult to demonstrate in animal models,
which are primarily used to establish device safety rather
Fig 4. Whole-mount example histophotomicrographs
(DES) in porcine iliac arteries after 3 months (left panels
Sections are stained with toluidine blue and basic fuchsinthan device efficacy. Indeed, most published preclinical studies of coronary DES demonstrate decreased neointima
ormation at 28 days, but the effect is usually transient and
annot be reproduced at longer time points.7,24-26 The
ustained antiproliferative effect of Dynalink-E, lasting up
o 6 months in this experiment, can probably be attributed
o its exceptionally long elution profile.
Also demonstrated in this study is the novel observation
hat Dynalink-E DESs attenuated the development of ex-
erimental arterial neoatherosclerosis. Neoatherosclerosis
s a pathologic process characterized by the accelerated
ormation of new atherosclerotic lesions after intravascular
tent implantation. Similar to de novo atherosclerosis, the
esions are typified by foamy macrophage infiltration and
holesterol cleft formation and, in the advanced stages,
ature plaques with central necrosis and overlying throm-
us.27 An analogous process has been described in human
ein grafts in which autologous venous conduits trans-
lanted into the arterial circulation are prone to atheroscle-
otic degeneration after several years.28
The etiology of neoatherosclerosis is speculative, al-
hough endothelial dysfunction, ongoing inflammation,
nd chronic mismatch of mechanical compliance almost
ertainly play a role.27 Given that DESs are generally
hought to promote neoatherosclerosis,27 the antiathero-
clerotic effect of everolimus in this model was an unex-
ected finding. However, everolimus has been found to
xert profound antiproliferative, anti-inflammatory, and
ntineoplastic effects in a number of preclinical models and
linical disease states, including (1) attenuation of neointi-
al hyperplasia in preclinical models in which everolimus is
elivered in culture,29 orally,8,30 or via DES,7 (2) reduction
f restenosis after stenting for coronary or peripheral occlu-
erlapped bare metal stent (BMS) or drug-eluting stent
onths (middle panels), and 12 months (right panels).of ov
), 6 mive disease,3-5 (3) prevention of rejection after solid organ
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Volume 56, Number 6 Zhao et al 1685transplantation,31 (4) reduction of the severity and inci-
dence of cardiac allograft vasculopathy,32 (5) suppression
of a variety of solid tumors, including breast, colorectal,
pancreatic, renal, lung, skin (melanoma), prostate, ovarian,
hepatic, and brain (glioblastoma, astrocytoma),6 and, fi-
nally, (6) control of hematologic malignancies such as acute
myelogenous and chronic lymphocytic leukemia.33 In the
United States, everolimus has gained approval as adjunctive
chemotherapy for advanced renal cell carcinoma,34,35 ad-
vanced pancreatic neuroendocrine tumors,36 and sub-
ependymal astrocytoma associated with tuberous sclerosis
(Afinitor; Novartis).37 Interestingly, it has recently been
suggested that everolimus, when formulated on intravascu-
lar bioresorbable scaffolds, may actually slow the progres-
sion of underlying atherosclerotic plaques.38 The drug’s
well-known inhibitory effect on macrophages has been
cited as a possible mechanism, given that transformation of
macrophages into lipid-foam cells is an important step in
atherogenesis. In a similar fashion, it is not unreasonable to
speculate that the related process of accelerated neoathero-
Table. Histologic results after overlapped BMS or DES im
3 months
Stent area, mm2
BMS 42.16  2.25
DES 39.53  2.12
P value .123
Neointimal thickness, mm
BMS 0.79  0.20
DES 0.37  0.04
P value .034
Lumen area, mm2
BMS 23.95  2.17
DES 28.85  1.31
P value .154
Area stenosis, %
BMS 41.37  6.73
DES 26.75  1.29
P value .040
Endothelialization, %
BMS 100  0.00
DES 100  0.00
P value NA
Inflammation score
BMS 2.29  0.44
DES 0.17  0.17
P value .001
Struts with fibrin, %
BMS 1.72  0.71
DES 25.36  5.37
P value .003
Struts with granuloma, %
BMS 18.63  12.57
DES 0.51  0.51
P value .188
Neoatherosclerosis score
BMS 0.56  0.15
DES 0.042  0.04
P value .003
BMS, Bare metal stent; DES, drug-eluting stent; NA, not applicable.
Data are presented as means  SEM; n  8 for each group and time point.sclerosis might also be effectively treated with everolimus. pIn a parallel to most preclinical studies of DES that
nclude longer time points, the favorable cellular effects of
ynalink-E in this experiment were transient. Statistically
ignificant reductions in inflammation, neointimal hyper-
lasia, and neoatherosclerosis were observed 6months after
tenting; however, no such differences between DESs and
MSs were detected after 12 months. A similar phenome-
on was observed in the clinical study of the Dynalink-E
evice. The SFA Treatment with Drug-Eluting Stents
STRIDES) trial was a prospective, nonrandomized, single-
rm, multicenter clinical study designed to evaluate the
afety and performance of Dynalink-E for the treatment of
therosclerotic peripheral arterial disease.39 One hundred
our patients with severe symptomatic vascular disease were
nrolled, including significant proportions of patients with
LI (17%), diabetes (39%), and single-vessel outflow
26%). The mean lesion length was 9.0  4.3 cm. The
esults showed that, after 6 months, primary patency was an
mpressive 94%  2.3%. However, the apparent antiprolif-
rative effect appeared to wane and, by 12 months, primary
tation in the porcine iliac arteries
6 months 12 months
44.84  1.25 48.00  0.66
44.86  1.94 44.75  2.28
.991 .157
0.73  0.14 0.68  0.11
0.41  0.08 0.67  0.11
.050 .923
27.25  2.07 31.22  2.20
32.49  1.65 28.71  1.16
.072 .158
38.80  5.09 34.80  4.77
27.25  2.99 34.77  3.88
.060 .996
100  0.00 100  0.00
99.96  0.04 100  0.00
.351 NA
2.06  0.43 1.00  0.25
0.50  0.50 2.56  0.62
.007 .110
0.96  0.70 0.26  0.26
13.97  3.96 0.43  0.30
.008 .261
3.21  2.84 0.00  0.00
6.01  6.01 16.62  8.51
.704 .092
0.84  0.23 0.094  0.10
0.00  0.00 0.19  0.19
.004 .927planatency had decreased to a disappointing 68%  4.6%.
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December 20121686 Zhao et alWhether the loss of patency was due to inadequate drug
delivery, too short of an elution profile, persistent chronic
outward force of the self-expanding nitinol stent against the
vessel wall, or inherent drug resistance of end-stage SFA
lesions, it is clear that the development of effective drug-
device combinations for the peripheral vasculature is con-
Fig 5. Histologic examples of stent-inducted neoather
presence of severe neoatherosclerosis, including chole
accumulation, and fat infiltration. b, BMS at 6 months.
months. Sections were stained with toluidine blue basicsiderably more challenging than for the coronary arteries. dIn summary, sustained local arterial delivery of everoli-
us inhibited the formation of neointimal hyperplasia and
eoatherosclerosis in a preclinical model of PPI. It is hoped
hat the persistent problem of peripheral arterial restenosis
an be successfully approached through the continued de-
elopment of devices that facilitate sustained intravascular
osis. a, Bare metal stent (BMS) at 3 months. Note the
clefts visible as void spaces, surrounding foamy cell
MS at 12 months. d, Drug-eluting stents (DES) at 12
in.oscler
sterol
c, Belivery of antiproliferative agents and that overcome the
11
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 6 Zhao et al 1687inherent problem of placing a permanent self-expanding
implant in the dynamic arterial environment of the lower
extremity.
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